Bavarian Nordic’s travel-health business benefits from strong vaccine demand. Sales of its chikungunya vaccine Vimkunya, which was approved in the U.S. and the European Union in February 2025, soared 415% in the second quarter, while revenue from its TBE shot Encepur rose 58%.
News
Global warming widens spread of TBE, chikungunya, Bavarian Nordic boss says
August 24, 2026Bavarian Nordic’s travel-health business benefits from strong vaccine demand. Sales of its chikungunya vaccine Vimkunya, which was approved in the U.S. and the European Union in February 2025, soared 415% in the second quarter, while revenue from its TBE shot Encepur rose 58%.